Mesothelioma Drug CRS-207: 3 Things You Should Know

The New York asbestos attorneys at The Williams Law Firm, P.C., will be watching with interest as the California pharmaceutical company Aduro Biotech moves forward with clinical testing and preliminary marketing of the new mesothelioma immunology drug CRS-207.

The company reported in a press release dated March 26, 2015, that the Office of Orphan Product Development of the U.S. Food and Drug Administration (FDA) has approved the drug, which already had FDA approval to treat pancreatic cancer.

“We believe the combination of CRS-207 together with chemotherapy may offer the promise of a potential new therapeutic regimen for patients suffering from mesothelioma,” Dirk Brockstedt, Aduro’s senior vice president of research and development, said in the press release.

Here are three key points from Aduro about preliminary research of CRS-207 to treat mesothelioma:

• THE DRUG WAS DEVELOPED FOR PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA WHO HAVE NOT RECEIVED PRIOR THERAPY AND ARE NOT ELIGIBLE FOR SURGERY.
• PATIENTS ARE CURRENTLY BEING ENROLLED IN CLINICAL TRIALS OF THE DRUG IN COMBINATION WITH STANDARD-OF-CARE CHEMOTHERAPY.
• INTERIM RESULTS PRESENTED AT THE INTERNATIONAL MESOTHELIOMA INTEREST GROUP CONFERENCE IN OCTOBER 2014 DEMONSTRATED A 94 PERCENT RATE OF DISEASE CONTROL FOR A TEST GROUP OF 16 PATIENTS. (SEVENTY-FIVE PERCENT OF THE PATIENTS, OR 12 OF 16, REPORTED PARTIAL RESPONSES TO THE DRUG; 19 PERCENT, OR 3 OF 16, EXPERIENCED STABLE DISEASE.)

When you have questions about mesothelioma treatment options or asbestos exposures in New York that cause mesothelioma, contact one of our attorneys online to schedule a consultation or call 855-575-MESO (6376).